Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...
“Recently, Eli Lilly announced the results from its SURMOUNT-5 trial, comparing Zepbound and Wegovy’s efficacy on equal grounds,” GlobalData’s analysis said. “Zepbound, as ...
The typical starting dose of Zepbound is 2.5 milligrams (mg). You’ll inject this dose once per week for 4 weeks. After that, your doctor may increase your dosage to 5 mg once per week.
In their respective third-quarter earnings reports, the companies tallied sales of $1.26 billion for Zepbound—falling short ...
The mean baseline blood glucose levels (expressed in mg/dL) were 88.2±9.0 for oral DehydraTECH-tirzepatide and 87.8±11.3 for injected Zepbound®, compared to the Study-ending levels of 83.2±5.7 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback